Sökning: onr:"swepub:oai:DiVA.org:uu-5736" >
TARP Promoter-Based...
TARP Promoter-Based Prostate Cancer Gene Therapy : From Development to Application
-
- Cheng, Wing-Shing, 1974- (författare)
- Uppsala universitet,Enheten för klinisk immunologi
-
Essand, Magnus (preses)
-
Tötterman, Thomas H. (preses)
-
visa fler...
-
- Lundberg, Cecilia, Docent (opponent)
- Institutionen för fysiologiska vetenskaper, Wallenberg Neuroscience Center, Lund Universitet, Lund
-
visa färre...
-
(creator_code:org_t)
- ISBN 9155462057
- Uppsala : Acta Universitatis Upsaliensis, 2005
- Engelska 57 s.
-
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 24
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://uu.diva-port...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Prostate cancer is one leading cause of cancer-related death among men in Western countries. The standard therapies for localized prostate cancer include radical prostatectomy and radiation therapy. Such measures are relatively effective in the short term, but many patients ultimately relapse. These patients may benefit from a combination of standard therapy and oncolytic virus therapy. My work aimed to develop viruses for this purpose.TARP is a protein that in males is specifically expressed in prostate epithelial and cancer cells. In my thesis, I characterized the TARP promoter and showed that TARP expression is regulated at the transcriptional level by testosterone through binding of the androgen receptor in the proximal TARP promoter. I further developed TARP promoter-based regulatory sequences for prostate-specific gene expression. A sequence comprising a PSA enhancer, a PSMA enhancer and the TARP promoter was constructed and designated PPT. An adenoviral vector containing the PPT sequence shielded from transcriptional interference by an H19 insulator showed high prostate-specific transcriptional activity in human cells both in the presence and absence of testosterone. However, in experimental murine prostate cancer the PPT sequence is not active. Therefore, a two-step transcriptional amplification (TSTA) system was used together with the PPT sequence to develop an adenovirus that confers prostate-specific transgene expression also in murine cells.I constructed a conditionally replicating adenovirus where the E1A gene expression is controlled by an H19 insulator-shielded PPT regulatory sequence, Ad[I/PPT-E1A]. This virus exhibited absolute prostate specificity in terms of E1A expression, viral replication and cytolysis in vitro and in vivo. Importantly, our virus is active both in the presence and absence of testosterone, which may prove beneficial for patients treated by hormonal withdrawal. Hopefully, my work will improve existing gene therapy strategies for prostate cancer and in the long term improve the prognosis for patients with prostate cancer.
Ämnesord
- TEKNIK OCH TEKNOLOGIER -- Industriell bioteknik -- Annan industriell bioteknik (hsv//swe)
- ENGINEERING AND TECHNOLOGY -- Industrial Biotechnology -- Other Industrial Biotechnology (hsv//eng)
Nyckelord
- Genetic engineering
- TARP
- PPT
- TSTA
- promoter
- gene regulation
- prostate specificity
- hormone- independent
- adenovirus
- prostate cancer
- gene therapy
- conditionally replicating adenovirus
- Genteknik
- Genetic engineering including functional genomics
- Genteknik inkl. funktionsgenomik
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas